Category: Press Release

Download PDF Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Feb. 12, 2013– AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 31, 2013– AVEO Oncology (NASDAQ:AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2012 will be released before the market opens on Wednesday, February 13, 2013. The AVEO management team will host a conference call discussing the company’s financial results, recent developments and detailed TIVO-1 findings on Wednesday, February 13,

Download PDF CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Jan. 29, 2013– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16 in Orlando, Florida. The schedule for tivozanib

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 24, 2013– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported that it has closed its recently announced public offering of common stock. The total number of shares sold was 7,667,050, comprised of 6,667,000 shares of common stock initially offered and an additional 1,000,050 shares of common stock sold pursuant to the underwriters’ exercise

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 22, 2013– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 1,000,050 shares, the full amount of the option granted to the underwriters, at the public offering price of $7.50 per share. All of the shares are

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 17, 2013– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 6,667,000 shares of its common stock at a price of $7.50 per share to the public. All of the shares are being sold by AVEO. The gross proceeds to AVEO from this offering are expected to be

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 16, 2013– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by AVEO. J.P. Morgan Securities LLC is acting as sole book-running manager for the proposed offering, with RBC Capital Markets,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 27, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2013 at 11:00 a.m. (PT) in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A

Download PDF Ronald A. DePinho, M.D. Retires from AVEO Board of Directors CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 20, 2012– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Robert Epstein, M.D., M.S. to its Board of Directors, and that Ronald A. DePinho, M.D. will retire from the AVEO Board effective December 31, 2012. Dr. DePinho co-founded AVEO and has served as

Download PDF BATON-BC Trial Initiation Marks Entry into Third Tumor Type for Tivozanib Clinical Development Program CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Dec. 3, 2012– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the initiation of patient enrollment in a randomized, double-blind, multicenter Phase 2 clinical trial, called BATON-BC, evaluating the efficacy of tivozanib, an investigational drug, in combination with